36 recruiting, 17 completed, 7 not yet recruiting, 5 unknown. 77 Phase 1, 15 Phase 2.
Follow Myositis: new trials by email Literature Review of Myositis trials Research Report on Myositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 1 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2026-12-01 | 2026-09-02 |
| A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Not yet recruiting | Pfizer | 54 | 2026-11-19 | 2026-10-01 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| A Study to Test CRT-402 in Refractory Autoimmune Disease CRT-402 - Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Recruiting | Myeloid Therapeutics | 34 | 2026-08-26 | 2026-10-22 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Study to Assess CLBR001+SWI019 in Subjects With Autoimmune Diseases CLBR001 + SWI019 - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Withdrawn | Calibr, a division of Scripps Research | 2026-03-01 | 2026-03-05 | |
| YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis | Phase 1 | Not yet recruiting | Children's Hospital of Fudan University | 12 | 2026-03-01 | 2026-02-27 |
| A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases XmAb657 - Healthy, Idiopathic Inflammatory Myopathies | Phase 1 | Recruiting | Xencor, Inc. | 60 | 2026-02-24 | 2026-08-03 |
| A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) GSK5926371 - Systemic Lupus Erythematosus | Phase 1 | Recruiting | GlaxoSmithKline | 44 | 2026-02-10 | 2026-06-23 |
| A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM) LUCAR-G79D T cells - Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM) | Phase 1 | Recruiting | Nanjing Legend Biotech Co. | 38 | 2026-01-29 | 2026-02-02 |
| A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases TI-0032-III injection - Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS) | Phase 1 | Recruiting | Therorna | 12 | 2026-01-22 | 2026-10-19 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| A Study of AZD0120 in Autoimmune Diseases AZD0120, SOC - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 27 | 2026-01-09 | 2026-11-10 |
| An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN) | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-24 | 2026-03-04 |
| Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis | Phase 1 | Recruiting | China Immunotech (Beijing) Biotechnology Co., Ltd. | 18 | 2025-11-13 | 2026-03-02 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Recruiting | Allogene Therapeutics | 66 | 2025-11-13 | 2026-11-02 |
| Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy - Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis | Phase 1 | Withdrawn | Beijing Boren Hospital | 2025-11-06 | 2026-10-15 |
Showing 20 of 77. Sign in to see all of them.
Lupus Erythematosus, Systemic (39) · Scleroderma, Systemic (38) · Dermatomyositis (29) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (21) · Arthritis, Rheumatoid (16) · Sjogren's Syndrome (15) · Autoimmune Diseases (14) · Lupus Nephritis (14) · Antiphospholipid Syndrome (10) · Polymyositis (10) · Scleroderma, Diffuse (10) · Myositis, Inclusion Body (7) · Arthritis, Juvenile (4) · Multiple Sclerosis (4)
Musculoskeletal Diseases (74) · Muscular Diseases (73) · Nervous System Diseases (72) · Neuromuscular Diseases (72) · Skin and Connective Tissue Diseases (61) · Connective Tissue Diseases (59) · Skin Diseases (57) · Immune System Diseases (53) · Autoimmune Diseases (40) · Joint Diseases (32) · Rheumatic Diseases (31) · Arthritis (29) · Cardiovascular Diseases (24) · Vascular Diseases (24)
Cyclophosphamide (10) · fludarabine (10) · tocilizumab (2) · (11C)-MC1 (1) · Bendamustine Hydrochloride (1) · CTLA-4 Antigen (1) · Cefadroxil (1) · Celecoxib (1) · Cephalexin (1) · Denosumab (1) · Etanercept (1) · Immunotherapy, Adoptive (1) · Interleukin-2 (1) · Ipilimumab (1) · Midazolam (1)
China Immunotech (Beijing) Biotechnology Co., Ltd. (5) · Chongqing Precision Biotech Co., Ltd (4) · Amgen (2) · AstraZeneca (2) · Chugai Pharmaceutical (2) · Fate Therapeutics (2) · Johns Hopkins University (2) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (2) · Peking University Third Hospital (2) · Abcuro, Inc. (1) · Adicet Therapeutics (1) · Allogene Therapeutics (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Boren Hospital (1) · Beijing GoBroad Hospital (1)
United States (36) · China (23) · France (10) · Germany (9) · Spain (9) · Australia (8) · Canada (6) · Poland (6) · Italy (5) · Japan (5) · Netherlands (4) · Czechia (3) · Romania (3) · Taiwan (3) · United Kingdom (3)
Adam Raff, MD, PhD (1) · Andrew Haynes, MD (1) · Ann Woolfrey (1) · Anthony A Amato, MD (1) · Carol A. Wallace, MD (1) · Chuan Qin (1) · Daehyun Yoo, MD (1) · Daishi Tian (1) · David Fiorentino, MD, PhD (1)
PMID 21688301, PMID 23434567, PMID 25322757, PMID 29728298, PMID 32359360, PMID 33258553, PMID 35470301, PMID 37804430, PMID 38172601, PMID 40152935, PMID 41501497, PMID 41562506, PMID 41832158, PMID 42177178
2018 (1), 2023 (1), 2025 (1), R01NS049639 (1), UM1CA186688 (1)